Revolution Medicines Presents RASolute 302 Clinical Trial Results at ASCO

Having treated patients and seen up close what metastatic pancreatic cancer can do, and so very quickly, the additional 6.5 months of overall survival in the SECOND LINE setting with a Once Daily PILL, without chemo, would have been priceless. Thirteen months of median overall survival in second line is Tremendous unheard of news for patients bringing infinite advantage, and to be treated with an amazing Pan KRAS inhibitor oral pill adds more value by preserving quality of life and keeping patients away from toxicities associated with standard of care chemo regimens. No doubt in mind the presentation of results at ASCO 2026 Plenary session will receive a standing ovation with this landmark clinical data. Better news for patients is that the FDA gave the green light for an extended access program so daraxonrasib will be available prior to formal approval. Bravo. 👏

We are entering an era of "plenty" in neuroendocrine oncology, with a growing toolkit of somatostatin analogs, PRRT, and targeted therapies like cabozantinib and everolimus. This activity discusses the evidence for sequencing these agents and balancing efficacy with patient quality of life. Claim 1.0 CME/NCPD/CPE/AAPA credit: https://bit.ly/41QP3Xd

We’re pleased to share that the Phase 3 PEAK trial has been selected for an oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. We’ll present data from our trial of bezuclastinib in combination with sunitinib in patients with GIST who have received prior treatment with imatinib. Read more here: https://bit.ly/3QzSaA4 #ASCO26

The selection of Cogent’s Phase 3 PEAK trial for an oral presentation at #ASCO26 is a major win for the GIST community. For years, the bar for second-line GIST has remained stubbornly low. Seeing bezuclastinib combination data show a 50% reduction in the risk of progression compared to the current standard of care is exactly the kind of progress the field requires. Huge congratulations to Andrew Robbins, John Robinson, and the entire Cogent Biosciences team for this much-awaited data. It is rare to see results that so clearly challenge the status quo—this is scientific innovation that changes lives. #ASCO2026 #PrecisionMedicine #Biotech #GIST #Oncology

ALX Oncology: 22-Month Median PFS in CD47-High Cohort: ALX reports CD47-high cohort median PFS of 22 months and plans interim ASPEN-09 data from ~80 patients by mid-2027; implications for pipeline and partners. http://dlvr.it/TSS3j5 👈 Read full analysis #ALXOncology #ClinicalTrials #CancerResearch #PFS #CD47

I highly recommend our recent LinkedIn Live about the newest consensus-based recommendations for outcomes (PROs) in oncology! Kelly Dumais, Ph.D., VP of eCOA Science at Clario was joined by Dr. Andrew Bottomley, co‑author of the recent PRO guidance published in The Lancet Oncology. They discussed what the updated recommendations mean for endpoint strategy, protocol design and operational planning across oncology development. Check it out! #ClarioOncology #PatientReportedOutcomes #ClinicalTrials

I highly recommend our recent LinkedIn Live about the newest consensus-based recommendations for outcomes (PROs) in oncology! Kelly Dumais, Ph.D., VP of eCOA Science at Clario was joined by Dr. Andrew Bottomley, co‑author of the recent PRO guidance published in The Lancet Oncology. They discussed what the updated recommendations mean for endpoint strategy, protocol design and operational planning across oncology development. Check it out! #ClarioOncology #PatientReportedOutcomes #ClinicalTrials

Our latest research in CJNM unveils a "double-hit" mechanism against LUSC: Sanguinarine induces both apoptosis and ferroptosis. By binding to BiP and activating the PERK/eIF2α/CHOP axis, this natural compound bypasses traditional resistance pathways. A significant lead for oncology drug development. 🧬🔬   🔗 Read more: https://lnkd.in/gK8zG8fk #Oncology #DrugDiscovery #LungCancer #NaturalProducts #CJNM

First-in-human oncology studies are shaped by a series of early decisions that can have lasting consequences for timelines, execution, and overall study success. @Bin Pan highlights why early-phase oncology development demands careful planning from the start, especially when key choices around design, dose escalation, patient population, and operational strategy can be difficult to reverse later. Read our ERGOMED guide to learn more: https://lnkd.in/e4zfU8Ga #FirstInHuman #OncologyTrials #EarlyPhaseDevelopment #ClinicalTrials

What's next for CAR T-cell therapies? Experts will address ongoing challenges and future directions during a Special Session at #AACR26, jointly organized by the AACR and the American Society of Clinical Oncology (ASCO). Learn more in AACR Annual Meeting News: https://brnw.ch/21x1JFi